It is a cytogenetic technique that is used to detect/localize DNA sequneces on chromosomes. Flourescent in-situ Hybridization (FISH) is a big word, to understand it better, let’s break it down. Flourescent – flourescent probes.  The flourescent probes are made from  fragments of DNA that were isolated, purified, and amplified for use in the Human Genome...Read More

Position of The CML Society of Canada Regarding the Issue of Generic imatinib in Canada On April 2, 2013 Health Canada approved two generic versions of imatinib mesylate (Gleevec®, Novartis) for sale in Canada; both Apotex and TEVA, two large generic manufacturers, have been granted approval of their bio-equivalent alpha crystal formulations of imatinib mesylate....Read More

GLEEVEC® is indicated for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase. GLEEVEC® is also indicated for the treatment of adult patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase or in chronic phase (after failure of interferon-alpha therapy). GLEEVEC® is also...Read More

Raising Awareness was our Key Motivator! There are about 5,100 Canadians living with CML. Every day someone in Canada is diagnosed with CML Although we have made significant improvements, once a week someone living with CML in Canada will die. No known cause or prevention of CML Some patients in Canada still struggle to access and/or pay...Read More

We are excited to announce that there is another new option that will soon be available for Canadian CML patients in Canada.  Pending Pan Canadian Oncology Drug Review and INESS Approval. ARIAD ANNOUNCES APPROVAL OF ICLUSIG (AS PONATINIB HYDROCHLORIDE) IN CANADA Cambridge, MA, April 6, 2015 –- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), today announced that...Read More

ICLUSIG ™ ICLUSIG ™ (Ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ALL that is T315I mutation positive or...Read More

Import Expert Panel advice for CML Patients: Advice for people with chronic myeloid leukemia on COVID-19The iCMLf is sharing an expert statement specifically for chronic phase CML patients on the novel coronavirus and the COVID-19 disease. The novel Coronavirus and the COVID-19 DiseaseInformation for Chronic Phase Chronic Myeloid Leukemia PatientsState of the Art as of...Read More

Notice regarding independent patient activities linked to the generic imatinib mesylate issue:  The CML Society of Canada does not endorse or condone independent patient activity that is aimed at inciting other patients, friends and family members to SPAM government offices with email alleging that generic imatinib mesylate is harmful to patients.  In fact there is...Read More

It is with great sadness that we mark the passing of Dr. Connie Eaves. Dr. Franc Nicolini from the FLMC group wrote a very touching memoriam for Dr. Eaves, click on the link below: C. Eaves pour le site Fi-LMC vdef 10.03.2024Read More

Novartis Pharmaceuticals Canada Inc. (Novartis) has received approval from Health Canada for PrJAKAVI® (ruxolitinib tablets), a drug for the treatment of disease-related splenomegaly (enlarged spleen) and/or its associated symptoms in adult patients with myelofibrosis (MF), a blood cancer.[i] PrJAKAVI® is the first and only JAK 1 and JAK 2 inhibitor approved by Health Canada for...Read More